Phase 4 N=68 Effects of N-acetylcysteine on Low T3 Syndrome
Acute Myocardial Infarction · Euthyroid Sick Syndrome · Ischemic Heart Disease
Primary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFrEF
Heart Failure With Reduced Ejection Fraction (HFrEF) · Low T3 Syndrome
Primary: Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment — 11; 19 Number of participants with events
Phase 2 N=45 Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Low T3 Syndrome
Primary: Free T3 (FT3) Levels — 3.6; 4.5; 3.9; 3.6 pg/ml — p=<0.05
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFpEF
Heart Failure With Preserved Ejection Fraction · Low Triiodothyronine Syndrome
Primary: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats — 10; 12 Number of participants with events
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
N/A N=51 Study of T3 for the Treatment of Fibromyalgia
Fibromyalgia
Primary: Visual Analogue Scale of Pain Intensity — 6.75; 5.71; 5.13; 6.19 Units on a scale
Phase 3 N=11 Liothyronine (T3) for Bipolar Depression
Depression · Bipolar Disorder
Primary: Hamilton Rating Scale for Depression Scores — 3.50; 7.25 units on a scale
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
N/A N=14 Mechanistic Study of Subclinical Hypothyroidism In the Elderly
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
Phase 3 N=220 Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Congenital Heart Defects
Primary: Time To Extubation — 46.9; 48.0 hours — p=<.05
Phase 3 N=70 Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Cardiac Surgery Intensive Care Treatment · Delayed Recovery From Anaesthesia · Euthyroid Sick Syndrome
Primary: Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ) — 6.65; 2.69 Score on a scale
Phase 1 N=15 Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Multiple Sclerosis
Primary: Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS — 75 mcg daily with BID dosing
Phase 2 N=22 Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
Healthy
Primary: Cardiac Output — -3.7; -1.4; 1 millilitres
Phase 2 N=284 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
Hypothyroidism · Thyroid Disease · Euthyroid
Primary: Percentage of Participants With a Sustained TSH Response — 60.76; 75.92 percentage of participants
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
N/A N=16 Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine
Growth Hormone Treatment · Aging
Primary: Percent Change of Triiodthyronine Over Baseline — -3.3; -6.1 percent change
Phase 3 N=31 Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
Healthy Volunteers
Primary: Energy Expenditure — 1.37; 1.40; 1.28; 1.27 kcal/min — p=0.0001
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 2 N=25 Oral Testosterone for the Treatment of Hypogonadism in Males
Hypogonadism
Primary: Percentage of Responders — 67; 57; 50; 100 percentage of subjects
Phase 4 N=50 Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism
Subclinical Hypothyroidism
Primary: Participants' Willingness to Enter the Trial — 52 Participants
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
N/A N=8,584 Low Indexes of Metabolism - Information to Teams (LIMIT)
Weight Loss · Thinness · Malnutrition
Primary: Death From Any Cause — 285; 245 Participants